These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20068388)

  • 1. Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
    Dobson CL; Main S; Newton P; Chodorge M; Cadwallader K; Humphreys R; Albert V; Vaughan TJ; Minter RR; Edwards BM
    MAbs; 2009; 1(6):552-62. PubMed ID: 20068388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo.
    Lei G; Xu M; Xu Z; Gu L; Lu C; Bai Z; Wang Y; Zhang Y; Hu H; Jiang Y; Zhao W; Tan S
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28953230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.
    Secchiero P; Sblattero D; Chiaruttini C; Melloni E; Macor P; Zorzet S; Tripodo C; Tedesco F; Marzari R; Zauli G
    Int J Immunopathol Pharmacol; 2009; 22(1):73-83. PubMed ID: 19309554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
    Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
    Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2.
    Tamada T; Shinmi D; Ikeda M; Yonezawa Y; Kataoka S; Kuroki R; Mori E; Motoki K
    Sci Rep; 2015 Dec; 5():17936. PubMed ID: 26672965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of p38 Activation and Mitochondria in Death of Human Leukemia Cells Induced by an Agonistic Human Monoclonal Antibody Fab Specific to TRAIL Receptor 1.
    Lee YR; Hwang E; Jang YJ
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
    Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
    J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
    Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
    Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
    Gieffers C; Kluge M; Merz C; Sykora J; Thiemann M; Schaal R; Fischer C; Branschädel M; Abhari BA; Hohenberger P; Fulda S; Fricke H; Hill O
    Mol Cancer Ther; 2013 Dec; 12(12):2735-47. PubMed ID: 24101228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel Epitopes with Agonistic Activity for the Development of Tumor Immunotherapy Targeting TRAIL-R1.
    Guo L; Sun X; Hao Z; Huang J; Han X; You Y; Li Y; Shen M; Ozawa T; Kishi H; Muraguchi A; Jin A
    J Cancer; 2017; 8(13):2542-2553. PubMed ID: 28900492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel humanized anti-tumor necrosis factor-related apoptosis-inducing ligand-R2 monoclonal antibody induces apoptotic and autophagic cell death.
    Chen L; Qiu Y; Hao Z; Cai J; Zhang S; Liu Y; Zheng D
    IUBMB Life; 2017 Sep; 69(9):735-744. PubMed ID: 28748573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation.
    Mühlenbeck F; Schneider P; Bodmer JL; Schwenzer R; Hauser A; Schubert G; Scheurich P; Moosmayer D; Tschopp J; Wajant H
    J Biol Chem; 2000 Oct; 275(41):32208-13. PubMed ID: 10807904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a novel fully human monovalent antigen-binding fragment on the survival of cancer cell lines.
    Kwon YS; Lee YR; Kim YS; Lee HW; Jang YJ
    Oncol Rep; 2007 Aug; 18(2):513-7. PubMed ID: 17611678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.
    Feng Y; Xiao X; Zhu Z; Dimitrov DS
    MAbs; 2010; 2(5):565-70. PubMed ID: 20581445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
    Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
    Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway.
    Hao Z; Han X; Sun X; Shen M; Huang J; Li Y; Ozawa T; Pang D; Jin S; Kishi H; Muraguchi A; Jin A
    Biochem Biophys Res Commun; 2016 Jun; 475(2):238-44. PubMed ID: 27208782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.